Sun Pharma-Organon deal lifts shares 9% in 2026

Shares jump as deal details land on the tape

Shares of Sun Pharmaceutical Industries rose sharply on Monday, April 27, 2026, after the company said it would acquire US-based Organon & Co in an all-cash transaction at an enterprise valuation of US$ 11.75 billion. The move was among the largest overseas acquisitions announced by an Indian company, and the market reaction was immediate. On the BSE, Sun Pharma opened at Rs 1,632.50, up Rs 12.55 from the previous close of Rs 1,619.95. With volumes rising more than 4.69 times, the stock climbed to an intraday high of Rs 1,766.65, a gain of 9.06%. Later in the session, it was last seen at Rs 1,737, up Rs 117.05 or 7.23% from the prior close. Sun Pharma’s market capitalisation at the time was Rs 4,16,754.67 crore.

What Sun Pharma is buying and what it is paying

Sun Pharma and Organon said they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$14.00 per share in cash. The companies pegged the transaction’s enterprise value at about US$ 11.75 billion, including debt. The acquisition is structured as a merger of Organon with a subsidiary of Sun Pharma, with Organon surviving the merger. Both boards have approved the transaction, according to the joint announcement.

Funding mix and leverage expectations

Sun Pharma said it plans to fund the acquisition through a combination of available cash resources and committed financing from banks. The company currently has around US$ 3.1 billion cash on its books, as cited in the reporting. Management indicated it would take on a sizeable amount of debt to complete the transaction, with leverage expected at around 2.3 times combined EBITDA. The company also said reducing debt quickly would be a key priority after the deal closes. Separately, Macquarie’s commentary cited in the coverage said it sees Sun Pharma returning to a debt-free status in 3-4 years.

Strategic rationale: biosimilars and broader global reach

Sun Pharma said the acquisition presents a strong growth opportunity and would significantly expand its global scale, product portfolio and market reach. The deal is expected to mark Sun Pharma’s entry into biosimilars and strengthen its position in several international markets, including Europe, China, South Korea, Mexico and Thailand. Coverage also described the transaction as expanding Sun Pharma’s global footprint, particularly in women’s health, biosimilars and established medicines. Another stated outcome is that, on completion, Sun Pharma would be on track to become one of the top three global players in women’s health.

What changes in scale look like on pro forma numbers

The combined company is expected to have pro forma revenue of about US$ 12.4 billion after the acquisition, according to the reported estimates. The same reporting said the combined entity would rank among the top 25 global pharmaceutical companies. Separately, the announcement noted that the deal provides access to over 70 products sold across more than 140 countries. The biosimilars angle was also quantified in the coverage, which said the combined company would become the seventh-largest player globally in biosimilars.

Organon’s profitability and cash generation cited in reports

The reported background on Organon included financial profile metrics that investors typically watch in large cash transactions. Over the past five years, Organon has maintained EBITDA margins of around 30%, according to the coverage. It has also generated nearly US$ 1.0 billion in pre-financing free cash flow over the same period, as cited. These figures were highlighted alongside Sun Pharma’s leverage plan, as the buyer prepares to balance deal funding with post-close deleveraging goals.

Market reaction: Sun Pharma in India, Organon in the US

In India, Sun Pharma’s rally was accompanied by a notable jump in trading activity, with BSE volumes up more than 4.69 times as the stock touched Rs 1,766.65 intraday. On the NSE, the stock was reported trading around Rs 1,740.00 in morning deals, up 7.33%. In the US, Organon’s stock reaction was also sharp around the deal newsflow. Reports said Organon stock surged roughly 31% on Friday when reports first emerged, and then climbed a further roughly 15% in Monday premarket trading, putting the two-session move at roughly 46% from pre-news levels. Another data point cited was Organon’s Friday close of US$ 11.26, up 30.93%.

Deal timeline and closing conditions

The companies said the transaction is expected to close in early 2027. Completion is subject to customary conditions, including regulatory approvals and approval by Organon stockholders. The structure, as described, is a merger of Organon with a Sun Pharma subsidiary, with Organon surviving the merger. Sun Pharma also disclosed that after completion, the acquired entity will merge with its subsidiary, consistent with the transaction mechanics outlined.

Key numbers at a glance

Why the deal matters for investors

For Sun Pharma shareholders, the immediate focus is the trade-off between larger global scale and the debt required to fund an all-cash acquisition. Management’s stated priority of reducing debt quickly, alongside a reported leverage expectation of about 2.3x combined EBITDA, framed the debate on balance-sheet risk. The strategic case rests on entering biosimilars and widening reach in multiple international markets, which the company highlighted as a way to expand its product lineup and market access. The market’s initial response was positive, with the stock rising as much as 9% intraday and volumes jumping more than four-fold.

Conclusion

Sun Pharma’s proposed acquisition of Organon at an enterprise value of US$ 11.75 billion triggered a sharp rally in its shares as investors weighed the strategic expansion against the planned leverage. The next major milestones are the regulatory process and Organon shareholder approval, with the companies guiding to an early 2027 closing timeline.